Study of new onset hyperglycemia and insulin resistance in COVID-19 patients
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20253260Keywords:
COVID-19, Glucose metabolism, Accessibility, Insulin resistance, New onset hyperglycemia, SARS-CoV-2Abstract
Background: COVID-19 has been associated with new onset hyperglycemia and insulin resistance, even in patients without pre-existing diabetes. This study aimed to evaluate the prevalence and characteristics of new onset hyperglycemia and insulin resistance in COVID-19 patients.
Methods: This case-control study included 90 COVID-19 patients admitted to Era’s Lucknow Medical College and Hospital. Patients were divided into a case group with new onset hyperglycemia (n=57) and a control group with normoglycemia (n=33). Fasting blood glucose, post-prandial glucose, HbA1c, fasting insulin, and HOMA-IR were measured. Disease severity and outcomes were also assessed.
Results: The prevalence of new onset hyperglycemia was 61.1% among COVID-19 patients. The case group had significantly higher mean fasting glucose (132.11 versus 90.43 mg/dl, p<0.001), post-prandial glucose (212.53 versus 157.91 mg/dl, p<0.001), HbA1c (5.86% versus 4.03%, p<0.001), fasting insulin (9.24 versus 7.67 μU/ml, p=0.004), and HOMA-IR (2.99 versus 1.72, p<0.001) compared to controls. Insulin resistance was present in 71.9% of cases versus 0% of controls (p<0.001). There was no significant difference in disease severity or mortality between groups.
Conclusions: New onset hyperglycemia and insulin resistance are common in COVID-19 patients, even without pre-existing diabetes. This metabolic dysregulation may contribute to worse outcomes and requires further study. Glucose monitoring and management should be considered in all hospitalized COVID-19 patients.
Metrics
References
Worldometer. Worldometer COVID-19 data. Available from https://www.worldometers.info/ coronavirus/about. Accessed 27 July 2020.
Singh AK, Gillies CL, Singh R, Singh A, Chudasama Y, Coles B, Seidu S, Zaccardi F, Davies MJ, Khunti K. Prevalence of co‐morbidities and their association with mortality in patients with COVID‐19: a systematic review and meta‐analysis. Diabetes Obes Metab. 2020;22(10):1915-24. DOI: https://doi.org/10.1111/dom.14124
Jivanji CJ, Asrani VM, Windsor JA, Petrov MS. New-onset diabetes after acute and critical illness: a systematic review. Mayo Clin Proc. 2017;92:762-73. DOI: https://doi.org/10.1016/j.mayocp.2016.12.020
Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, Klonoff DC. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Tech. 2020;14(4):813-21. DOI: https://doi.org/10.1177/1932296820924469
Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID‐19. Diabetes Obes Metab. 2020;22(10):1897-906.
Unsworth R, Wallace S, Oliver NS, Yeung S, Kshirsagar A, Naidu H, et al. New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K. Diabetes Care. 2020;43:e170-1. DOI: https://doi.org/10.2337/dc20-1551
McGlacken-Byrne SM, Drew SEV, Turner K, Peters C, Amin R. The SARS-CoV-2 pandemic is associated with increased severity of presentation of childhood onset type 1 diabetes mellitus: a multi-centre study of the first COVID-19 wave. Diabetes Med. 2021;38:e14640. DOI: https://doi.org/10.1111/dme.14640
Tittel SR, Rosenbauer J, Kamrath C, Ziegler J, Reschke F, Hammersen J, et al. Did the COVID-19 lockdown affect the incidence of pediatric type 1 diabetes in Germany? Diabetes Care. 2020;43(11):e172. DOI: https://doi.org/10.2337/dc20-1633
Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Res Clin Pract. 2020;167:108382. DOI: https://doi.org/10.1016/j.diabres.2020.108382
Song S, Dong Y, Wang X, Wang Y, Hao Y, Wang Y, et al. Association between longitudinal change in abnormal fasting blood glucose levels and outcome of COVID-19 patients without previous diagnosis of diabetes. Front Endocrinol. 2021;12:640529. DOI: https://doi.org/10.3389/fendo.2021.640529
Coppelli A, Giannarelli R, Aragona M, Penno G, Falcone M, Tiseo G, et al. Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: The Pisa COVID-19 Study. Diabetes Care. 2020;43(10):2345-8. DOI: https://doi.org/10.2337/figshare.12682526
Wang S, Ma P, Zhang S, Song S, Wang Z, Ma Y, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020;63(10):2102-11. DOI: https://doi.org/10.1007/s00125-020-05209-1
Li H, Tian S, Chen T, Chen L, Liu H, Zhang X. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020;22(10):1897-906. DOI: https://doi.org/10.1111/dom.14099
Montefusco L, Ben Nasr M, D’Addio F, Loretelli C, Rossi A, Pastore I, et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021;3(6):774-85. DOI: https://doi.org/10.1038/s42255-021-00407-6
Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gómez-Escobar LG, Ma L, et al. Hyperglycemia in acute COVID-19 is characterized by adipose tissue dysfunction and insulin resistance. Cell Metab. 2021;33(11):2174-88.e5. DOI: https://doi.org/10.1016/j.cmet.2021.09.009
Hanley B, Naresh KN, Roufosse C, Nicholson AG, Weir J, Cooke GS, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020;1(6):e245-53. DOI: https://doi.org/10.1016/S2666-5247(20)30115-4
Hollstein T, Schulte DM, Schulz J, Glück A, Ziegler AG, Bonifacio E, et al. Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. Nat Metab. 2020;2(10):1021-4. DOI: https://doi.org/10.1038/s42255-020-00281-8
Wang Q, Ren J, Morgan J, Liu Z, Dou C, Liu B, et al. Myeloperoxidase deletion prevents high-fat diet-induced obesity and insulin resistance. Diabetes. 2014;63(12):4172-85. DOI: https://doi.org/10.2337/db14-0026
Chai W, Danser AHJ, Eringa EC. Inhibiting myeloperoxidase prevents onset and reverses established high-fat diet-induced microvascular insulin resistance. Am J Physiol Endocrinol Metab. 2019;317(6):E1063-9. DOI: https://doi.org/10.1152/ajpendo.00203.2019
Mughal A, O’Rourke ST. Vascular effects of apelin: mechanisms and therapeutic potential. Pharmacol Ther. 2018;190:139-47. DOI: https://doi.org/10.1016/j.pharmthera.2018.05.013
Gourdy P, Cazals L, Garcia C, Teissèdre F, Melliere D, Ninane N, et al. Apelin administration improves insulin sensitivity in overweight men during hyperinsulinemic-euglycemic clamp. Diabetes Obes Metab. 2018;20(1):157-64. DOI: https://doi.org/10.1111/dom.13055
Zhang C, McFarlane C, Lokireddy S, Bonala S, Ge X, Masuda S, et al. Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. Diabetologia. 2011;54(6):1491-501. DOI: https://doi.org/10.1007/s00125-011-2079-7
Feldman BJ, Streeper RS, Farese RV Jr, Yamamoto KR. Myostatin modulates adipogenesis to generate adipocytes with favorable metabolic effects. Proc Natl Acad Sci USA. 2006;103(42):15675-80. DOI: https://doi.org/10.1073/pnas.0607501103
Martin D, Allagnat F, Gesina E, Caille D, Gjinovci A, Waeber G, et al. Functional significance of repressor element 1 silencing transcription factor (REST) target genes in pancreatic beta cells. Diabetologia. 2008;51(8):1429-39. DOI: https://doi.org/10.1007/s00125-008-0984-1
Wu D, Shu T, Yang X, Song JX, Zhang M, Yao C, et al. Plasma metabolomic and lipidomic alterations associated with COVID-19. Nat Sci Rev. 2020;7(7):1157-68. DOI: https://doi.org/10.1093/nsr/nwaa086
Tirosh A, Shimon I, Shapiro H, Tov AB, Shalitin S, Levi R, et al. The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans. Sci Transl Med. 2019;11(489):120. DOI: https://doi.org/10.1126/scitranslmed.aav0120
Heimann E, Nyman M, Degerman E. Branched short-chain fatty acids modulate glucose and lipid metabolism in primary adipocytes. Adipocyte. 2016;5(4):359-68. DOI: https://doi.org/10.1080/21623945.2016.1252011
Downloads
Published
How to Cite
Issue
Section
